Inonotus obliquus — from folk medicine to clinical use

Konrad A. Szychowski a, *, Bartosz Skóra a, Tadeusz Pomianek b, Jan Gmiński a

a Department of Lifestyle Disorders and Regenerative Medicine, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225, Rzeszow, Poland
b Department of Management, Faculty of Administration and Social Sciences, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225, Rzeszow, Poland

A B S T R A C T

The Inonotus obliquus (I. obliquus) mushroom was traditionally used to treat various gastrointestinal diseases. For many years, mounting evidence has indicated the potential of I. obliquus extracts for treatment of viral and parasitic infections. Furthermore, substances from I. obliquus have been shown to stimulate the immune system. The most promising finding was the demonstration that I. obliquus has hypoglycemic and insulin sensitivity potential. This review summarizes the therapeutic potential of I. obliquus extracts in countering the progression of cancers and diabetes mellitus as well as their antiviral and antiparasitic activities and antioxidant role. As shown by literature data, various authors have tried to determine the molecular mechanism of action of I. obliquus extracts. Two mechanisms of action of I. obliquus extracts are currently emerging. The first is associated with the broad-sense impact on antioxidant enzymes and the level of reactive oxygen species (ROS). The other is related to peroxisome proliferator-activated receptor gamma (PPARγ) effects. This receptor may be a key factor in the anti-inflammatory, antioxidant, and anti-cancer activity of I. obliquus extracts. It can be concluded that I. obliquus fits the definition of functional food and has a potentially positive effect on health beyond basic nutrition; however, studies that meet the evidence-based medicine (EBM) criteria are needed.

© 2020 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Inonotus obliquus (I. obliquus) (Ach. ex Pers.) Pilát, belonging to the family Hymenochaetaceae, is a black-brown plant parasitic fungus.1,2 This mushroom has also at least a few common and regional names such as [Pol.] czerniak brzozy, czyreń, czernidło, czarci oko, or czanga, which most likely has been coined from the Russian word “chaga”.3 The genus Inonotus is widespread in North America, Asia, and Europe and includes approximately 100 species.3,4 In Europe, this genus is represented only by 4 species, with I. obliquus as one of them.4 Although it is widely distributed in North America, Asia, and Europe, I. obliquus is on the list of partially protected species of mushrooms in Poland.5

I. obliquus is a primary tree parasite causing decomposition of live trunks.6 It has been seen on many trees species such as alder, beech, maple, rowan, hornbeam, poplar, oak, ash, willow, plane-tree, chestnut, and walnut, but the main hosts of I. obliquus are various species of birch.3,7 It should be noted that the reports on the occurrence of I. obliquus on different species of deciduous trees are not reliable, because other fungi of the genus Inonotus are very often confused with the analyzed species.3,7

I. obliquus infects approximately 30–50-year-old trees through wounds in the bark and can grow on the trunk for another 30–80 years.3,5 A few years after penetrating the trunk of live trees, it produces sclerotia (vegetative or asexual fruiting bodies) with a lumpy irregular shape, cracked surface, and black-brown color. The interior of the sclerotium itself is made of rust-brown, yellow-veined, very dense mycelium.7 The sclerotia grow very slowly, reaching a diameter of more than 10 cm after 10–15 years.5 On old trees, the growths can exceed 50 cm in diameter.3 After many years, the host tree dies and annual fruiting bodies of the sexual stage appear. Fruiting bodies of this stage develop in the warm season of
the year in places with the most advanced rot. They very rarely grow on live trees. 3,8 This type of fruiting bodies may have considerable sizes (up to 3–4 m in length and up to 50 cm in width) and are eaten very quickly by insects, which are assumed to be the main (besides the wind) spore-spreading vector of *I. obliquus*. 3

Numerous scientific studies have shown that the assumptions of folk medicine beliefs are reasonable. Mexican and European folk medicine plants have been tested on *in vivo* or *in vitro* models, e.g. *Jasminum fruticans*, *Mentha longifolia*, and *Artemisia absinthium* extracts, which show anthelmintic or antibacterial effects. 9,10 Given these examples, the search for new potentially active, natural compounds in folk medicine extends the present knowledge and help to find a promising cure to such prevalent diseases as cancers, parasitic infestations, or bacterial infections. Therefore, the usefulness of *I. obliquus* extract in medicine, e.g. in the treatment of diabetes and parasitic and viral infections, was evaluated. However, there has been no work so far, presenting the current scientific findings on *I. obliquus* in a concise and substantive form. Therefore, the aim of this work is to present the current state of knowledge of the biological properties of the *I. obliquus* mushroom and the potential possibilities of its medical use.

### 2. Application of *I. obliquus* in folk medicine

In folk medicine, rational premises are intertwined with elements of magic. The rational premises are based on observation of the natural environment and finding substances that alleviate disease symptoms. In many countries, this is the only way in which people can improve their health due to poverty in society or difficult access to scientific medicine. *I. obliquus* has been used in folk medicine since ancient times. One of the oldest documents confirming the use of its conks for medicinal purposes is the work by Hippocrates “Corpus Hippocraticum”. The father of medicine used infusions of this mushroom externally to wash wounds.

In Eastern Europe, the Chaga mushroom has been used since the 12th century. Historical sources describe healing of a lip tumor in a Kiev Kniaž. 11 *I. obliquus* was used in traditional medicine for many indications by the people of Siberia. 12 The fungus was applied due to its antiparasitic, anti-tuberculosis, anti-inflammatory, and gastrointestinal properties. 13 It was also recommended for heart and liver diseases. Most often, it was used in the form of infusions, inhalations, or aqueous macerates. 13 Also antiseptic soaps containing *I. obliquus* were prepared for external use. In the middle of the 20th century, Chaga infusions were used as a substitute for tea in Siberia. 14 Relatively early attention was paid to the potential *I. obliquus* antitumor or supportive effect in cancer treatment, which was particularly important before the era of scientific oncology. Such descriptions can be found in popular literature, e.g. in Aleksander Solzhenitsyn’s *Cancer Ward*. 14

In Asia (China, Japan, Korea), Russia, and the Baltic countries, extracts of Chaga mushroom were used due to their beneficial effects on the plasma lipid system and heart function as well as antibacterial, anti-inflammatory, and anti-cancer activity. 15 Furthermore, the antioxidant activity of *I. obliquus* may be important for prevention of free radical-related civilization diseases (atherosclerosis, cancer, diabetes, accelerated aging, and degenerative diseases of the central nervous system). 15 Chaga extracts have been shown to inhibit the reproduction of hepatitis C virus (HCV) and human immunodeficiency viruses (HIV). 15

The only objective method to assess the effectiveness of any therapy in scientific medicine is to perform research that meets the criteria of evidence-based medicine (EBM). Unfortunately, no observations from folk medicine or folk tales meet these criteria. Therefore, while drawing information from these sources, it is necessary to conduct scientific research that will either refute or confirm the folk premises. Importantly, the highest EBM standards should be maintained during the research, giving grounds for verifying folk knowledge.

### 3. Chemical composition and approaches to extraction of substances from *I. obliquus*

Only young and fresh sclerotia growing on birches, harvested throughout the year, are used in medicine. 7 Sclerotia should be harvested in uncontaminated areas distant from sources of pollution, which may accumulate in the fungus. 18 In the natural
environment, *I. obliquus* grows in a cool climate with high seasonal temperature fluctuations, freezing, UV radiation, as well as occurrence of bacterial and viral infections. In response to numerous stressors, *I. obliquus* has developed complex defense mechanisms. These mechanisms include the production of various bioactive substances: antioxidants, triterpenoids, ergosterol and its peroxide, sesquiterpenes, benzoic acid derivatives, hspisn analogues, and melanins. In addition, high expression of antioxidant enzymes has been detected in *I. obliquus*. Moreover, many reports have highlighted that the polysaccharide fraction present in *I. obliquus* extracts is the largest group of active compounds, besides phenols. Therefore, many investigations have been performed to evaluate the polysaccharide content in this mushroom extracts, also in various conditions of extraction such as freeze, hot air, or vacuum drying methods. As reported by Ma et al. *I. obliquus* extracts contain many low molecular polysaccharides, which are considered antioxidant agents responsible for this activity of these mentioned extracts. This antiradical property has been repeatedly proved in the literature *inter alia* by Ma et al. or Cui et al. who tested the antioxidant properties of *I. obliquus* saccharides in *in vitro* or *in vivo* on rat livers, respectively. The water extract contained 19.76–26.51% of neutral sugars, in which the sugar composition varied depending on the drying method, but rhamnose, galactose, and glucose were the dominant sugars, whereas arabinose or mannose were the least abundant components. The chemical structure of *I. obliquus* polysaccharides was also strictly related to the method applied, indicating that the saccharides were characterized by a dense spherical, branching, and elongated rod structure.

Currently, many approaches for isolation of substances from *I. obliquus* have been described; they are summarized in Table 1. They can be divided into techniques yielding the whole of isolated substances, individual fractions, or even single active substances from *I. obliquus*. The use of total aqueous or ethanol extracts is the most similar approach to the methods used in folk medicine. These types of extracts are suitable for direct consumption. Unfortunately, the application of other methods of total extraction using organic solvents such as methanol, ethyl acetate, or cyclohexane prevents the use of such a product. From a practical point of view, the use of a whole extract in scientific research is very important for practical natural or herbal medicine. In addition, many substances present in the whole extract can abolish or enhance each other’s activity. On the other hand, it is not possible to investigate the exact mechanism of specific substances in a non-fractionated extract. Another approach is to use individual fractions obtained from *I. obliquus*. In the literature, there are descriptions of research on various substances isolated from *I. obliquus*, including melanin, indothiol, flavans, triterpenoids, steroids, polyphenols, or polysaccharides. This type of approach makes it possible to determine precisely which substance has therapeutic effects. Currently, the most frequently performed research is focused on the polysaccharide fraction (summarized in Table 1). As shown in the literature, this is a very promising group of substances associated with anti-cancer activity and insulin-improving sensitivity. It should be noted that proteins contained in extracts are not studied. The extraction methods denature the protein at an early stage of isolation. In the case of aqueous extracts, the isolation of the substance is carried out at a temperature between 80 and 100 °C. Similarly, various organic solvents (ethanol, methanol, cyclohexane, etc.) as well as multi-stage extraction methods can destroy the bioactive active ingredients contained in *I. obliquus*.

### 4. Biological properties of *Inonotus obliquus* extracts

Many different properties of extracts or substances derived from *I. obliquus* have been described to date. These include antiviral, antiadipic, antioxidant, antiparasitic, immunomodulatory, anti-inflammatory, neuroprotective, anticancer properties in vitro, and recently antifatigue effects. Relevant literature data are summarized in Table 2.

#### 4.1. Antioxidant properties

The antioxidant properties of extracts and individual fractions of substances obtained from *I. obliquus* are the most frequently studied parameter in scientific publications. To determine the antioxidant potential, methods based on the stable 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) are used. Less often, another stable 2,2’-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical is used. DPPH and ABTS methods are based only on the antioxidant potential of chemical substances and do not fully reflect the antioxidant potential of a given extract or substance. Methods based on the impact on the activity or expression of antioxidant enzymes as well as the formation of reactive oxygen species (or scavenging) in living cells reflect better the actual state in the organism. To date, the effects of *I. obliquus* extracts on the activity and/or expression of antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), xanthine oxidase (XOD) in cell cultures and mouse tissues have been described. In addition, extracts from *I. obliquus* affected reactive oxygen species (ROS) production measured with the malonic dialdehyde (MDA) and 2’,7’-dichlorodihydrofluorescein diacetate (H₂DCFDA) methods. Interestingly, the effects were different depending on the type of cell. Szychowski et al. showed that extracts from *I. obliquus* reduced the amount of ROS in normal cells; in turn, numerous research teams described an increase in ROS in cancer cell lines.

Flavan derivatives, polysaccharides, and 3,4-dihydroxybenzalacetone isolated from *I. obliquus* have also been shown to have neuroprotective effects in neurodegenerative disease models such as Alzheimer and Parkinson diseases and the SH-SYSY cell line. These substances were found to protect against oxidative stress or increase SOD expression. Similarly, in other cells considered normal, such as pancreatic (RINm5F cell line) and hepatic (LO2 cell line) cells, *I. obliquus* polysaccharides protected against H₂O₂-induced damage.

#### 4.2. Anti-inflammatory and immunomodulatory effects

So far, few research teams have tried to determine the impact of extracts obtained from *I. obliquus* on the immune system. Fan et al. have shown that water-soluble polysaccharides obtained from

| Table 1 Approaches to isolation and administration of extracts or various substances isolated from *Inonotus obliquus*. |
| --- |
| TYPES OF EXTRACTS FROM *Inonotus obliquus* TESTED | REFERENCES |
| ENTIRE WATER EXTRACTS | 28,36,31,39,41–45 |
| ENTIRE ETHANOL EXTRACTS | 1,30,36,41–46 |
| ENTIRE METHANOL EXTRACTS | 30,32,41,49 |
| ENTIRE SODIUM HYDROXIDE EXTRACTS | 43 |
| ENTIRE CYCLOHEXANE EXTRACTS | 31 |
| ENTIRE ETHYL ACETATE EXTRACTS | 31 |
| MELANIN FRACTION | 24,29,50 |
| INODIOTOL FRACTION | 33,51 |
| FLAVAN FRACTION | 34 |
| TRITERPENOIDS AND STEROIDS FRACTIONS | 1,35,52–54 |
| POLYSACCHARIDE FRACTIONS | 1,37,62–64,38,55–61 |
| POLYPHENOLIC FRACTION | 1,32,36 |
**Table 2** Properties of different extracts from *Inonotus obliquus*. *In vitro* means a cell culture model or chemical analysis (cell-free model) *in vivo* means experiments performed on animals. To date, no human experiments have been performed.

| PROPERTIES OF DIFFERENT EXTRACTS FROM *Inonotus obliquus* | TYPE OF BIOLOGICAL MODEL USED | REFERENCES |
|----------------------------------------------------------|-------------------------------|------------|
| **ANTIVIRAL**                                            | *in vivo*                     | 17,39,72–74 |
| **ANTIDIABETIC**                                         | *in vivo/in vitro*            | 29,37,57,65,76 |
| **ANTIOXIDANT/ROS SCAVENGER**                            | *in vivo/in vitro*            | 1,39,39,69,70,75,77–82,83–87,87,42,50,55–58 |
| **ANTIFATIGUE**                                          | *in vivo*                     | 71          |
| **ANTI PARASITIC**                                       | *in vivo*                     | 63–65       |
| **IMMUNOMODULATORY**                                    | *in vivo/in vitro*            | 31,48,61,62,64,68–90 |
| **ANTI-INFLAMMATORY**                                    | *in vivo*                     | 31,48,61,57,60,61 |
| **NEUROPROTECTIVE**                                      | *in vivo/in vitro*            | 34,66,82,91 |
| **ANTI-CANCER POTENTIAL**                                | *in vitro*                   | 28,30,45,51,63,67,75,93–95,31,32,38,43–47 |

*I. obliquus* increased the proliferation of murine peritoneal lymphocytes. Polysaccharides from *I. obliquus* also stimulated the production of tumor necrosis factor-alpha (TNFα) by mouse macrophages, TNFα production increased in direct proportion to the increasing concentration of the tested polysaccharides. Similarly, Chen et al. observed that polysaccharides from *I. obliquus* increased the proliferation of splenocytes and lymphocytes. In addition, *I. obliquus* increased the secretion of cytokines such as interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-12 (IL-12), and TNFα and intensified the phagocytic processes. *I. obliquus* also significantly increased Bax expression and inhibition of Bcl-2. In turn, the latest research has shown that *I. obliquus* extracts very strongly reduced TNFα secretion in the RAW 264.7 cell line. Similarly, Chen et al. showed that polysaccharides from *I. obliquus* affected the Th1/Th2 lymphocyte ratio and Th17/Treg immune response. It is currently thought that *I. obliquus* extracts or their polysaccharide fraction inhibit inflammatory reactions. Most studies show a reduction in the production and/or secretion of proinflammatory cytokines such as interleukin-1 beta (IL-1β), interferon gamma (IFNγ), and TNFα. In *in vivo* studies showed that an *I. obliquus* extract administered to Sprague-Dawley rats for 7 days protected the animals against the development of induced inflammation. The same studies showed that the *I. obliquus* extract exhibited analgesic properties as well. Park et al. tried to elucidate the mechanism of the anti-inflammatory and analgesic effects of *I. obliquus* extracts on the RAW 264.7 cell line. It was demonstrated that the extract caused a decrease in the production of nitric oxide (NO) and prostaglandin E2 (PGE2). In addition, LPS-stimulated macrophages produced nitric oxide synthase (iNOS), which was inhibited by the *I. obliquus* extract. Furthermore, the tested extract inhibited lipo-polysaccharide (LPS)-induced cyclooxygenase-2 (COX-2) production.

The *I. obliquus* extract also reduced mRNA production and expression of TNFα and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) induced by LPS. Recent studies have shown that individual fractions from *I. obliquus* can act antagonistically. Wold et al. proved that some polysaccharide fractions increased NO production by murine macrophage and dendritic cell lines J774 A1 and D2SC/1. It cannot be excluded that, depending on the type of cells tested, the extracts or individual substances from *I. obliquus* may increase or inhibit NO production.

4.3. **Antiviral, antibacterial, and antiparasitic properties of *I. obliquus***

Data on the antiviral activity of *I. obliquus* extracts are very limited. To date, it has been shown that polysaccharides derived from the aqueous fraction of *I. obliquus* inhibit the protease from HIV type 1 (HIV-1), and thus impede the entry of virions into cells. In other studies, Shihnev et al. showed that the *I. obliquus* water extract was active against the HCV. At 48 h after addition of the *I. obliquus* aqueous extract to the HCV-infected embryonic porcine kidney epithelial inoculated line (SPEV), the amount of the virus in the cells was inversely proportional to the concentration of the added extract. At the highest concentrations, the extract completely stopped or significantly inhibited the reproduction of HCV. Moreover, it was shown that the addition of the extract to the cells 24 h before their exposure to the virus protected the SPEV cells from infection. In another experiment, an aqueous extract of *I. obliquus* showed an effect against the herpes virus - Herpes simplex type 1 (HSV-1) in normal kidney cells (Vero) of infected *Cercopithecus aethiops*. The presented studies confirm the antiviral effect of *I. obliquus* and indicate its potential use in the treatment of diseases associated with viral infections. In addition, the polysaccharide fraction of *I. obliquus* exhibited a broad-spectrum antiviral activity against feline herpesvirus 1, feline influenza virus H3N2 and H5N6, feline panleukopenia virus, and feline infectious peritonitis virus, which cause respiratory and gastrointestinal diseases in cats. Similarly, Seo and Choi showed that ethanolic extracts from *I. obliquus* inhibited the entry of murine norovirus (MVNV) and feline calcivirus (FCV) into RAW264.7 cells.

In the available literature, there are only two reports suggesting the antibacterial or probiotic effect of *I. obliquus* extracts. Niu et al. showed that various fractions derived from *I. obliquus* stimulated NO production and additionally increased phagocytosis in RAW 264.7 cells. As demonstrated by Hu et al. *I. obliquus* polysaccharide was found to regulate the gut microbiota in chronic pancreatitis in mice. Moreover, the authors suggest that administration of *I. obliquus* polysaccharides could regulate the gut microbiota composition and diversity to a healthy profile in mice with chronic pancreatitis.

To date, only one team has studied the antiparasitic aspects of *I. obliquus* extracts and polysaccharides. *Toxoplasma gondii* (*T. gondii*) is an obligate intracellular protozoan that causes toxoplasmosis in humans and many warm-blooded animals. Approximately 30%–50% of the population is infected with *T. gondii* worldwide. Xu et al. described that *I. obliquus* polysaccharides significantly reduced the abortion rate, inhibited the decreases in progesterone (P) and estriol (E3) levels and the increase in the MDA level, and increased the activities of SOD and CSH. Furthermore, *I. obliquus* polysaccharides inhibited the production of inflammatory cytokines, such as TNFα, IL-6, IFNγ, IL-1β, and IL-17A, and promoted the production of the anti-inflammatory cytokine interleukin-10 (IL-10) and transforming growth factor (TGF)-β in *T. gondii*-infected pregnant mice. Similarly, Xu et al. described that *I. obliquus* polysaccharides significantly decreased the liver coefficient and the levels of alanine aminotransferase (ALT),...
Table 3
Anti-cancer potential of extracts or substances isolated from *Inonotus obliquus* tested on different tumor cell lines.

| CANCER CELL LINE | ASSAYS                          | REFERENCES |
|------------------|---------------------------------|------------|
| A549 human lung adenocarcinoma | LDH release      | 28,95      |
|                  | Caspase-3 activity            | 67,95      |
|                  | DNA fragmentation               | 28,32,49,67,68,95 |
|                  | Cell viability                 | 28         |
|                  | Cell proliferation             | 95         |
|                  | ROS production                 |            |
|                  | Cytotoxicity                   | 31         |
| HeLa human cervical cancer       | Cell viability                | 40         |
|                  | Caspase-3 activity             | 49         |
|                  | Cell migration                 | 32         |
| 4T1 mouse mammary carcinoma     | Cell viability                | 47         |
| MCF-7 human breast cancer       | Cell viability                | 47,49,68   |
| AGS human gastric cancer        | Cell viability                | 49         |
| HEK-293 human embryonic kidney  | Cell viability                | 49         |
| PA-1 human ovarian teratocarcinoma | Cell viability          | 32         |
| U937 human myeloid leukemia cell | Cell viability              | 32         |
| HL-60 human myeloid leukemia    | Cell viability                | 32         |
| CACO-2 human colon carcinoma    | Cell viability                | 30         |
|                  | LDH release                    | 30         |
|                  | ROS production                 |            |
|                  | Cell proliferation             |            |
| HT-29 human colorectal adenocarcinoma | Cell viability         | 28,46      |
|                  | DNA synthesis                  |            |
|                  | Cell proliferation             | 28         |
|                  | LDH release                    | 95         |
| H1264 lung adenocarcinoma       | Cell viability                | 45         |
|                  | LDH release                    | 95         |
|                  | Caspase-3 activity             | 95         |
|                  | DNA fragmentation              | 95         |
| HCT-116 human colon carcinoma   | Cell viability                | 45         |
|                  | LDH release                    |            |
|                  | Caspase-3 activity             | 95         |
|                  | DNA fragmentation              |            |
|                  | Cell viability                 |            |
| B16–F10 murine skin melanoma    | Cell viability                | 44,48,93   |
|                  | Caspase-3 activity             | 44         |
|                  | Cell cycle inhibition          | 93         |
|                  | Cell migration                 | 93         |
| Calu-6 human pulmonary adenocarcinoma | LDH release            | 95         |
|                  | Caspase-3 activity             | 95         |
|                  | DNA fragmentation              |            |
|                  | Cell viability                 |            |
| HEC-1B human endometrial adenocarcinoma | Cell viability | 68         |
| P388 mouse leukemia           | Cell viability                | 94         |
|                  | Caspase-3 activity             | 94         |
|                  | DNA fragmentation              | 94         |
| Fao rat hepatoma            | Cell viability                | 28         |
|                  | Cell proliferation             | 28         |
|                  | LDH release                    | 28         |
|                  | Cell migration                 | 28         |
| P19 mouse embryo teratocarcinoma | Cell viability              | 28         |
|                  | Cell proliferation             | 28         |
|                  | LDH release                    | 28         |
|                  | Cell migration                 | 28         |
| C6 rat glioma             | Cell viability                | 28         |
|                  | Cell proliferation             | 28         |
|                  | LDH release                    | 28         |
| Hep3B human hepatoma        | Cell migration                 | 43,107     |
|                  | Cell viability                 | 43         |
|                  | Cell cycle inhibition          | 43         |
| HepG2 human hepatoma        | Cell viability                 | 43,107     |
|                  | Cell cycle inhibition          | 43         |
|                  | ROS production                 | 108        |
| Hur7 human hepatoma        | Cell viability                 | 68         |
| KATO-III human stomach carcinoma | Cell viability           | 68         |
| DLD-1 human colon carcinoma | DNA fragmentation            | 40         |
| SGC-7901 human gastric carcinoma | Cell viability          | 38         |
| SK-OV3 human ovary adenocarcinoma | Cell viability      | 68         |
| SW1156 kidney adenocarcinoma | Cell viability                | 68         |
| SW620 human colorectal adenocarcinoma | Cell proliferation | 105        |
aspartate aminotransferase (AST), MDA, and nitric oxide NO. In turn, the polysaccharides increased the levels of antioxidant enzymes SOD and GSH. As mentioned previously, *I. obliquus* polysaccharides also effectively decreased the expression of serum TNFα, IL-6, IL-1β, IFNγ, and interleukin-4 (IL-4) in *T. gondii*-infected mice. The authors found that *I. obliquus* polysaccharides down-regulated the levels of toll-like receptor 2 (TLR2) and toll-like receptor 4 (TLR4) and phosphorylation of NF-κB p65 and inhibitor kappaB (IκB), but up-regulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1). Lastly, Ding et al. showed that *I. obliquus* polysaccharides significantly improved the spermatogenic capacity, ameliorated pathological damage to testis, and increased the levels of serum testosterone, luteinizing hormone, and follicular-stimulating hormone in *T. gondii*-infected male mice. *I. obliquus* polysaccharides effectively up-regulated the expression of testicular steroidogenic enzyme in *T. gondii*-infected mice. The authors attributed this effect to the polysaccharides down-regulation of NF-κB expression in A549 induced by *T. gondii* extracts has been shown to inhibit proliferation and/or are cytotoxic to these human gastrointestinal tumor cell lines. Similarly, their cytotoxic, anti-proliferative, or pro-apoptotic effects have been demonstrated in cell lines from many other tissues and systems, e.g., lung, cervix, mammary gland, ovary, liver, lymphoid cancers (A549, MCF-7, HepG2, HepG3B, HeLa, MCF-7, HL-60, PA-1, H1286, H1299) (described in detail in Table 3). In publications elucidating the molecular mechanism of extracts, the authors consistently emphasize the role of ROS in the mechanism of action of substances derived from the extract. In publications elucidating the molecular mechanism of extracts, the authors consistently emphasize the role of ROS in the mechanism of action of substances derived from *I. obliquus*. The authors also agree that extracts from *I. obliquus* intensify the process of apoptosis measured by caspase-3 activity or the level of DNA fragmentation and stop the cell cycle in the G0 phase. Very important in migration/metastasis of tumors are matrix metalloproteinases (MMPs). It has been shown that although the *I. obliquus* extract was not toxic to the A549 cell line at low concentrations, it statistically significantly reduced cell migration. The authors attributed this effect to the declining MMP-2 and MMP-9 expression and the increasing expression of tissue metalloproteinase inhibitor-2 (TIMP-2) as well as the reduced expression of NF-xB. Similarly, a decrease in NF-xB expression in A549 induced by *I. obliquus* extracts has been described. Moreover, it has been reported that *I. obliquus* polysaccharides inhibit the expression of MMP-2, MMP-7, and MMP-9 in B16–F10 mouse cells. Recently, Zhang et al. described that inotodiol from *I. obliquus* decreases the expression of MMP-2 and MMP-9 in HeLa human cells and reduces cell invasiveness. Unfortunately, the tests performed in vivo are very limited. To date, it has been shown that tumors of the 3LL mouse lung cancer line implanted in C57BL/6 mice developed significantly more slowly in animals treated with an *I. obliquus* aqueous extract. In the experiment, it was shown that the tumor in mice receiving the extract was by 60% smaller and the number of metastases decreased by 25%. Interestingly, ingestion of *I. obliquus* reduced the body weight of the mice and increased their body temperature, which may have contributed to the protection against cancer, as suggested by the researchers. Furthermore, *I. obliquus* extracts have been shown to inhibit the development of two tumor lines: melanoma B16–F10 and sarcoma-180 after implantation into Balbc/c strain mice. It has also been shown that ergosterol isolated from *I. obliquus* inhibited the development of human colorectal cancer in the C57BL/6 mouse strain. It is currently believed that the high

Fig. 1. Proapoptotic and antioxidant action of *Inonotus obliquus* extracts in normal and neoplastic cells described in literature.
content of polysaccharides is responsible for the anti-cancer potential of *I. obliquus*. However, the anti-cancer potential have been found in all types of extracts used.

### 4.5. Hypoglycemic and insulin sensitivity action

ROS play a key role in many signaling pathways. Moreover, the relationship between oxidative stress and metabolic disorders such as type 2 diabetes (T2DM), cancer, obesity, and cardiovascular disease is well described. To date, it has been shown that *I. obliquus* polysaccharides have hypoglycemic activity. Unfortunately, the exact mechanism of action has not been elucidated. It has been described that *I. obliquus* polysaccharides in streptozotocin (STZ)-induced diabetic Wistar rats reduced blood glucose levels and restored the structure of β-cells after diabetes-induced cellular damage. *I. obliquus* polysaccharides lowered the level of lipid peroxidation products (such as low-density lipoprotein), whereas the high-density lipoprotein cholesterol level was enhanced. Moreover, Wang et al. reported that *I. obliquus* polysaccharides enhanced the serum levels of insulin and alleviated the metabolic derangement of glucose enzymes in STZ-induced diabetic mice. In the same experimental model, *I. obliquus* polysaccharides with the chromium (III) complex significantly decreased fasting blood glucose levels, plasma insulin levels, and body weight in mice. This is consistent with the previously described studies of total extracts. Cha et al. demonstrated that *I. obliquus* dietary treatment lowered serum glucose and leptin levels and alleviated obesity-related complications in T2DM OLETF rats. Similarly, Sun et al. described that feeding the experimental mice with *I. obliquus* improved serum insulin levels, moderately expanded the pancreatic islets, and reduced pancreatic injuries in alloxan-induced diabetic mice. In turn, *I. obliquus* polysaccharides elevated insulin levels in C57BL/6 mice with diabetic nephropathy; however, the cholesterol and triglyceride levels remained unaffected. Recently, *I. obliquus* polysaccharide has been reported to help to alleviate pancreatic acinar atrophy and weight loss in chronic pancreatitis mice induced by diethyldithiocarbamate. Hu et al. postulated that *I. obliquus* polysaccharides possessed strong antioxidant activity for scavenging free radicals in vitro and in vivo, which could be beneficial for chronic pancreatitis therapy in mice.

Peroxisome proliferator-activated receptor gamma (PPARγ) is a key receptor involved in insulin resistance and cell sensitivity to this hormone. Moreover, PPARγ is also involved in anti-inflammatory action, by controlling activation and expression of NF-xB and pro-inflammatory cytokines. However, only one paper showed that *I. obliquus* extract activated adipogenesis of 3T3-L1 preadipocytes, enhanced the expression PPARγ target genes, and increased triacylglycerol accumulation.

### 5. Conclusions and perspectives

For decades, extracts of *I. obliquus* have been used as a remedy for numerous diseases in folk medicine. Recent discoveries have provided evidence of the appropriateness of using these drugs in vitro. Extracts from *I. obliquus* prepared in various solvents as well as individual fractions of substances derived from the fungus show antiviral, antibacterial, immunostimulating, and anti-tumor activity in vitro. To date, various studies have suggested significant therapeutic potential of substances derived from *I. obliquus*. Based on the literature data, it can be concluded that the effectiveness of extracts and/or substances derived from *I. obliquus* is based on two main mechanisms. The first one is the effect of *I. obliquus* on the production of ROS and/or on mechanisms of ROS scavenging, which varies depending on the cell type. The proposed scheme of the effect is described in Fig. 1.

The other mechanism is based on the action via the PPARγ receptor. Experimental evidence suggests that extracts and/or substances obtained from *I. obliquus* may affect the level of expression or activity of the PPARγ receptor. In this way, extracts from *I. obliquus* can reduce insulin resistance. However, it cannot be excluded that the anti-cancer mechanism of action of *I. obliquus* extracts also involves the PPARγ receptor. The proposed scheme of the effects is described in Fig. 2. Unfortunately, due to the lack of data on the involvement of the PPARγ receptor in the anti-tumor activity of *I. obliquus* extracts, further research is required. It can be concluded that *I. obliquus* fits the definition of functional food and has a potentially positive effect on health beyond basic nutrition; however, studies that meet the EBM criteria are needed.

Taking the above into account, we suppose that the *I. obliquus* extracts can be included in cancer therapies in the future; however, more specialistic analysis should be performed, especially in *in vivo* models.

**CRediT authorship contribution statement**

**Konrad A. Szychowski**: Data curation, Formal analysis, Writing - original draft. **Bartosz Skóra**: Writing - original draft. **Tadeusz...**
Pomianek: Writing - original draft. Jan Gmínski: Writing - original draft.

Declaration of competing interest

The authors declare that there is no conflict of interest.

Acknowledgements

This work was supported by statutory funds from the University of Information Technology and Management in Rzeszow, Poland (DS 507-03-01 GW). The authors declare no conflict of interests.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jtcm.2020.08.003.

References

1. Cui Y, Kim D-S, Park K-C. Antioxidant effect of Inonotus obliquus. J Ethnopharmacol. 2005;96(1-2):79–85. https://doi.org/10.1016/j.jep.2004.08.037.
2. Dai YC. Polypore diversity in China with an annotated checklist of Chinese polypores. Mycoscience. 2012;53(1):49–80. https://doi.org/10.2522/0002-6675-011-0134-3.
3. Szczepkowski A, Pietka J, Gryzwa A. [Biological and medicinal properties of the chaga mushroom Inonotus obliquus (Fr.) P. Filat.] Sylwion. 2013;173(3): 223–231.
4. Wagner T, Fischer M. Natural groups and a revised system for the European poroid Hymenochaetales (Basidiomycota) supported by nLSU rDNA sequence data. Mycol Res. 2001;105(7):773–782. https://doi.org/10.1017/S0027551401000452.
5. Zheng W, Miao K, Liu Y, et al. Chemical diversity of biologically active metabolites in the sclerotia of Inonotus obliquus and submerged culture strategies for up-regulating their production. Appl Microbiol Biotechnol. 2010;87(4):1237–1254. https://doi.org/10.1007/s00253-010-1682-y.
6. Manka K, Kobiczewski P, Manka M, Fiedorow Z. Fitopatologia Lesna. Warszawa: Powiatowy Wydawnictwo Rolnicze i Lesne; 2005.
7. Ryvarden L, Gilbertson R, Eide A. European Polypores. Part 2: Meripilus-Tyromyces. In: Synopsis Fungorum. 7. Oslo: Fungiflora; 1994.
8. Chy J, Lee SY, Lee SY, Chun KW. Basidiocarp formation by Inonotus obliquus on a living paper birch tree. For Pathol. 2011;41(2):163–164. https://doi.org/10.1080/0301887X.2010.1063987.
9. Kozan E, Kupeli E, Ysidra E. Evaluation of some plants used in Turkish folk medicine against parasitic infections for their in vivo anthelmintic activity. J Ethnopharmacol. 2006;108(2):211–216. https://doi.org/10.1016/j.jep.2005.09.003.
10. Aghapoor K, Mohsensazadeh F, Shakeri A, Darabi HR, Ghassemzadeh M, Neumueller B. Catalytic application of recyclable silica-supported bismuth (III) chloride in the benzo [N, N]-heterocyclic condensation. J Organomet Chem. 2013;743:170–176. https://doi.org/10.1016/j.ijlipro.2013.09.052.
11. Perevedentseva L. Use of wild-growing mushrooms for therapeutic purposes in the perm territory, Russia. J Ethnopharmacol. 2011;135(2):131–136. https://doi.org/10.1016/j.jep.2011.04.014.
12. Youn M-J, Kim J-K, Park S-Y, et al. Chaga mushroom (Inonotus obliquus) in- duces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol. 2008;14(35):5368–540. https://doi.org/10.3748/wjg.14.5368.
Gastroenterol. 2008;14(4):511–517. https://doi.org/10.3748/wgj.14.511.

44. Youn MJ, Kim JK, yeol Park S, et al. Potential anticancer properties of the water extract of Inonotus obliquus by induction of apoptosis in melanoma B16-F10 cells. J Ethnopharmacol. 2009;121(2):221–228. https://doi.org/10.1016/j.jeph.2008.10.016.

45. Tsai CC, Li YS, Lin PP. Inonotus obliquus extract induces apoptosis in the human oral cancer cells, CAL-27, via HCT-116. Biomed Pharmacother. 2017;96(B):1189–1126. https://doi.org/10.1016/j.biopha.2017.11.111.

46. Lee HS, Kim EJ, Kim SH. Ethanol extract of Inonotus obliquus (Chaga mushroom) induces G1 cell cycle arrest in HT-29 human colon cancer cells. Nutr Res Pract. 2015;9(5):295–306. https://doi.org/10.5656/1975-7468-nprp-2015-05-011.

47. Zhao F, Xia G, Chen L, et al. Chemical constituents from Inonotus obliquus and their antimutagenic activities. J Nat Med. 2016;70(4):721–730. https://doi.org/10.1007/s11418-015-0922-4.

48. Liu X, Yu D, Li L, et al. Three-phase partitioning for the extraction and purification of polysaccharides from the immunomodulatory medicinal mushroom inonotus obliquus. Molecules. 2019;24(3):1–14. https://doi.org/10.3390/molecules24030040.

49. Cheng MJ, Chung C-K, Jeong Y, Ham S-S. Anticancer activity of substances containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in Balb/c mice bearing Sarcoma-180 cells. Nutr Res Pract. 2010;4(3):177–182. https://doi.org/10.4162/nrp.2010.4.3.177.

50. Burmasova MA, Utebaeva AA, Sysoeva EV, Sysoeva MA. Melanins of Inonotus obliquus: biogenic and biactive substances. Biomed Pharmacother. 2018;101:485–493. https://doi.org/10.1016/j.biopha.2018.04.047.

51. Wang J, Wang C, Li S, et al. Anti-diabetic effects of Inonotus obliquus polysaccharide and its amelioration for chronic pancreatitis in mice. Int J Biol Macromol. 2019;137:424–431. https://doi.org/10.1016/j.ijbiomac.2019.02.178.

52. Xu L, Sang R, Yu Y, Li J, Ge B, Zhang X. The polysaccharide from Inonotus obliquus by induction of apoptosis in melanoma B16-F10 cells. J Ethnopharmacol. 2019:131:769–778. https://doi.org/10.1016/j.jep.2019.03.031.

53. Jiang S, Shi F, Lin H, et al. Inonotus obliquus polysaccharides induces apoptosis of lung cancer cells and alters energy metabolism via the LKB1/AMPK axis. Int J Biol Macromol. 2020;151:1277–1286. https://doi.org/10.1016/j.jbiomac.2019.10.174.

54. Kim YO, Park HW, Kim JH, Lee JY, Moon SH, Shin CS. Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus. Life Sci. 2006;79(1):72–80. https://doi.org/10.1016/j.lfs.2005.12.047.

55. Eid J, Das B. Molecular insights and cell cycle assessment upon exposure to Chaga (Inonotus obliquus) mushroom polysaccharides in zebrafish (Danio rerio). Sci Rep. 2020;10(1):7406. https://doi.org/10.1038/s41598-020-6451-7.

56. Wang J, Wang C, Li S, et al. Anti-diabetic effects of Inonotus obliquus polysaccharide and its antioxidant activity. Sci Rep. 2016;6:1082. https://doi.org/10.1038/srep10824.

57. Zhang G, Guo YJ, Cheng H, et al. Spatial structure and anti-fatigue of polysaccharide from Inonotus obliquus. Int J Biol Macromol. 2020;151:853–860. https://doi.org/10.1016/j.jbiomac.2020.02.167.

58. Sim YC, Lee JS, Lee S, et al. Effects of polysaccharides isolated from Inonotus obliquus on pancreatic cells. Food Chem Toxicol. 2018;116(February):335–345. https://doi.org/10.1016/j.fct.2018.04.047.

59. Yong T, Chen S, Liang D, et al. Actions of inonotus obliquus against hyperuricemia through XOD and bioacids screened by molecular modeling. Int J Mol Sci. 2018;19(10):1–11. https://doi.org/10.3390/ijms19103222.

60. Xu X, Wu P, Wang T, Yan L, Lin M, Chen C. Synergistic effects of surfactant-assisted biodegradation of wheat straw and production of polysaccharides by Inonotus obliquus under submerged fermentation. Bioresour Technol. November 2018;209:43–50. https://doi.org/10.1016/j.biотechn.2019.01.022.

61. Niu H, Song D, Mu H, Zhang W, Sun F, Duan J. Investigation of three lignin complexes with antioxidant and immunological capacities from Inonotus obliquus. Int J Biol Macromol. 2016;86:587–593. https://doi.org/10.1016/j.jbiomac.2016.01.011.

62. Wold CW, Kjeldsen C, Cortatha A, et al. Structural characterization of bioactive heteropolysaccharides from the medicinal fungus Inonotus obliquus (Chaga). Carbohydr Polym. December 2017;188:27–40. https://doi.org/10.1016/j.carbohydrpol.2017.12.041.

63. Xu L, Sang R, Yu Y, Li J, Ge B, Zhang X. The polysaccharide from Inonotus obliquus protects mice from Toxoplasma gondii-induced liver injury. Int J Biol Macromol. 2018;118:254–262. https://doi.org/10.1016/j.jbiomac.2018.11.114.

64. Xu L, Yu Y, Sang R, et al. Inonotus obliquus polysaccharide protects against adverse pregnancy caused by Toxoplasma gondii infection through regulating Th17/Treg balance via TLR4/NF-kB pathway. Int J Biol Macromol. 2020;166:83. https://doi.org/10.1016/j.jbiomac.2020.04.267.

65. Ding X, Ge B, Wang M, et al. Inonotus obliquus polysaccharide ameliorates impaired reproductive function caused by Toxoplasma gondii infection in male mice via regulating Nrf2-PTKeAkt pathway. Int J Biol Macromol. 2019;125:1–8. https://doi.org/10.1016/j.jbiomac.2019.11.114.

66. Han Y, Nan S, Fan J, Chen Q, Zhang Y. Inonotus obliquus polysaccharides protect against Alzheimer’s disease by regulating Nrf2 signaling and exerting antioxidative and antipapoptotic effects. Int J Biol Macromol. 2019;131:769–778. https://doi.org/10.1016/j.jep.2019.03.031.

67. Zhang L, Lin D, Li H, et al. Immunopotentiating effect of Inonotus obliquus fermentation products administered at vaccination in chickens. Mol Cell Probes. 2018;41(July):43–51. https://doi.org/10.1016/j.molcelpro.2018.09.002.

68. Chen YF, Zheng JJ, Qi C, et al. Inonotus obliquus polysaccharide ameliorates...
dextran sulphate sodium induced colitis involving modulation of Th1/Th2 and Th17/Treg balance. Artif Cells Nanomed Biotechnol. 2019;47(1):757–766. https://doi.org/10.1080/21691401.2019.1577877.

90. Kim Y-R. Immunomodulatory activity of the water extract from medicinal mushroom inonotus obliquus. Mycobiology. 2005;33(3):158–162. https://doi.org/10.4489/MYCO.

91. Cho SY, Hur SJ, An CS, et al. Anti-inflammatory effects of inonotus obliquus in colitis induced by dextran sulphate sodium. J Biomed Biotechnol. 2010;2010:943516. https://doi.org/10.1155/2010/943516.

92. Gunjima K, Tomiyama R, Takakura K, et al. 3,4-dihydroxybenzalacetone protect against Parkinson’s disease-related neurotoxin 6-OHDA through Akt/NFkB signaling pathway. J Cell Biochem. 2014;115(1):151–160. https://doi.org/10.1002/jcb.24643.

93. Lee KR, Lee JS, Lee S, et al. Polysaccharide isolated from the liquid culture broth of Inonotus obliquus suppresses invasion of B16-F10 melanoma cells via AKT/NFkB signaling pathway. Mol Med Rep. 2016;14(5):4429–4435. https://doi.org/10.3892/mmr.2016.5771.

94. Nomura M, Takahashi T, Uesugi A, Tanaka R, Kobayashi S. Inotodiol, a lano-stane triterpenoid, from Inonotus obliquus inhibits cell proliferation through caspase-3-dependent apoptosis. Anticancer Res. 2008;28(5 A):2691–2696.

95. Baek J, Roh H-S, Baek K-H, et al. Bioactivity-based analysis and chemical characterization of cytotoxic constituents from Chaga mushroom (Inonotus obliquus) that induce apoptosis in human lung adenocarcinoma cells. J Ethnopharmacol. 2018;224:63–75. https://doi.org/10.1016/j.jep.2018.05.025.

96. Fu L, Chen H, Dong P, Zhang X, Zhang M. Effects of ultrasonic treatment on the physicochemical properties and DPPH radical scavenging activity of polysaccharides from mushroom Inonotus obliquus. J Food Sci. 2010;75(4):C322–C327. https://doi.org/10.1111/j.1750-3841.2010.01590.x.

97. Xiang Y, Xu X, Li J. Chemical properties and antioxidant activity of exopolysaccharides fractions from mycelial culture of Inonotus obliquus in a ground corn stover medium. Food Sci. 2012;13(4):1899–1905. https://doi.org/10.1016/j.foodchem.2012.03.121.

98. Xu X, Wu Y, Chen H. Comparative antioxidative characteristics of polysaccharide-enriched extracts from natural sclerotia and cultured mycelia in submerged fermentation of Inonotus obliquus. Food Chem. 2011;127(1):74–79. https://doi.org/10.1016/j.foodchem.2010.12.090.

99. Blois MS. Antioxidant determinations by the use of a stable free radical. Nature. 1958;181(4617):1199–1200. https://doi.org/10.1038/1811199a0.

100. Flegel A, Kim DO, Chung SJ, Koo SI, Chun OK. Comparison of ABTS/DPPH scavenging activities of sodium dextran sulphate sodium induced colitis involving modulation of Th1/Th2 and Th17/Treg balance. Artif Cells Nanomed Biotechnol. 2019;47(1):757–766. https://doi.org/10.1080/21691401.2019.1577877.

101. Li Z, Mei J, Jiang L, et al. Chaga medicinal mushroom, inonotus obliquus (agaricomycetes) polysaccharides suppress tacrine-induced apoptosis by ROS-scavenging and mitochondrial pathway in HepG2 cells. Int J Med Mushrooms. 2019;21(6):583–593. https://doi.org/10.1615/IntJMedMushrooms.2019030857.

102. Wang Q, Mu H, Zhang L, Dong D, Zhang W, Duan J. Characterization of two water-soluble lignin metabolites with antiproliferative activities from inonotus obliquus. Int J Biol Macromol. 2015;74:1020731:507–514. https://doi.org/10.1016/j.ijbiomac.2014.12.044.

103. Quintero-Fabian S, Arreola R, Recerier-Villanueva E, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol. 2019;9(December):1–21. https://doi.org/10.3389/fonc.2019.01370.

104. Chou Y-J, Kan W-C, Chang C-M, et al. Renal protective effects of low molecular weight polysaccharides from Chaga mushroom (Inonotus obliquus). Int J Mol Sci. 2014;15(6):2533–2540. https://doi.org/10.3390/ijms14262685.

105. Arata S, Watanabe J, Maeda M, et al. Continuous intake of the Chaga mush-room (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice. Helyon. 2016;2(5), e00111. https://doi.org/10.1016/j.helyon.2016.e00111.

106. Duru KC, Kovaleva EG, Danilova IG, Bjal P. The pharmaceutical potential and possible molecular mechanisms of action of Inonotus obliquus from preclinical studies. Phyther Res. 2019;33(8):1916–1980. https://doi.org/10.1002/ptr.6304.

107. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114. https://doi.org/10.1161/CIRCULATIONAHA.115.024060.

108. Liu P, Xue J, Tong S, Dong W, Wu P. Structure Characterization and Hypoglycaemic Activities of Two Polysaccharides from Inonotus obliquus. Molecules. 2018;23(8):1948. https://doi.org/10.3390/molecules23081948.

109. Wang M, Zhao Z, Zhou X, et al. Simultaneous use of stimulatory agents to enhance the production and hypoglycaemic activity of polysaccharides from inonotus obliquus by submerged fermentation. Molecules. 2019;24(23):4400. https://doi.org/10.3390/molecules24234400.

110. Chou Y-J, Kan W-C, Chang C-M, et al. Renal protective effects of low molecular weight polysaccharides from Chaga mushroom (Inonotus obliquus) on streptozotocin-induced diabetic symptoms and their potential mechanisms in rats. Evid Base Complement Alternat Med. 2014;2014:841496. https://doi.org/10.1155/2014/841496.

111. Cha JY, Jin BS, Yoo KS, Hahn JR, Cho YS. Fermented chaga mushroom (Inonotus obliquus) effects on hypolipidemia and hepatoprotection in Otsuka Long-Evans Tokushima fatty (OLETF) rats. Food Sci Biotechnol. 2006;15:122–127.

112. Sun J-E, Ao Z-H, Lu Z-M, et al. Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of inonotus obliquus in submerged culture on normal and alloxan-diabetes mice. J Ethnopharmacol. 2008;118(1):7–13. https://doi.org/10.1016/j.jep.2008.02.030.

113. Chen W, Liu C, Zhang J, et al. Renal protective effects of low molecular weight of inonotus obliquus polysaccharide (JIOP) on HF2-STZ-Induced nephropathy in mice. Int J Mol Sci. 2016;17(9):1535. https://doi.org/10.3390/ijms17091535.

114. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest. 2000;106(4):467–472. https://doi.org/10.1172/JCI10843.

115. Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biol. 2002;71(3):388–400. https://doi.org/10.1189/jlb.0701338.

116. Joo J, Kim DH, Yun JW. Extract of Chaga mushroom (Inonotus obliquus) stimulates 3T3-L1 adipocyte differentiation. Phyther Res. 2010;24(11):1592–1599. https://doi.org/10.1002/ptr.3180.